This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

A New Jersey-based pharmaceutical company is recalling three lots of liquid infant ibuprofen that might be more concentrated than advertised.

Tris Pharma’s voluntary recall covers Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 ml.

The company says there is a “remote possibility” that infants more susceptible to medication with a higher potency of ibuprofen might suffer permanent renal injury.

“Adverse effects that may be experienced are nausea, vomiting, epigastric pain, or more rarely, diarrhea,” according to Tris Pharma’s press release Wednesday. “Tinnitus, headache and gastrointestinal bleeding are also possible adverse effects.”

According to Tris Pharma, they have not received any reports of adverse effects.

Wholesalers and retailers should stop selling the affected lots and consumers with questions can call Tris Customer Service at 732-940-0358 or via email at Customer Service Email .

40.058324 -74.405661